Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

ABT 41.71 -0.19 (-0.45%)
price chart
Abbott Labs Approves $3 Billion in Buybacks
The buyback authorization is in addition to the $511 million remaining under Abbott's previous $3 billion share repurchase program, which was approved in June 2013.
Abbott Laboratories (ABT) Declares Quarterly Dividend, Announces Share ...
Abbott Labs (ABT) to Repurchase Shares for $3B
Related articles »  
Abbott Labs' 'Sugar High' is Just What the Doctor Ordered
Abbott Laboratories (ABT) - This medical device maker announced Wednesday that it received CE Mark for its FreeStyle Libre Flash Glucose Monitoring System.
Stock Update: Abbott Laboratories (NYSE:ABT) � Abbott Receives CE Mark for ...  Jutia Group
Abbott glucose monitor cleared in Europe (ABT)  Seeking Alpha (registration)
Related articles »  
Abbott Labs Presents Positive One-Year Data on Absorb
The vascular business is an important part of Abbott Labs' product portfolio generating sales of $1.5 billion in the first half of 2014.
Abbott Proves Its New Stent Technology As Non-Inferior To Its Own �Xience�  Bidness ETC
Abbott's Dissolving Heart Stent Clears Arteries in Trial  Bloomberg
Related articles »  
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
NEW YORK (TheStreet) -- By conventional valuation methods, shares of Abbott Laboratories (ABT) aren't expensive. In fact, it's easy to argue that Abbott is one of the best bargains in medical technology.
Related articles »  
Abbott Laboratories (ABT) Weak In Early Morning Trading
Abbott Laboratories manufactures and sells health care products worldwide. The stock currently has a dividend yield of 2%. ABT has a PE ratio of 31.7.
National medical device company to close Houston-area facility  Houston Business Journal
Abbott Laboratories Receives Consensus Rating of "Hold" from ...  WKRB News
Related articles »  
Abbott Laboratories: An Emerging Markets Growth Play With Increasing Dividends
Abbott Laboratories (NYSE:ABT) is a diversified healthcare products company that is now focused on nutritional products, diagnostics, generic drugs, and medical devices.
Related articles »  
Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals
ABBOTT PARK, Ill., Sept. 26, 2014 - Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets.
Company Update: Abbott Laboratories (NYSE:ABT) - Abbott Completes ...  Jutia Group
Abbott Labs Acquires Control Of CFR Pharma - Quick Facts  RTT News
Related articles »  
abbott laboratories
Specifically, the agency charged several drug makers -- including AbbVie, Abbott Laboratories, which spun off AbbVie, and Teva Pharmaceuticals -- for striking deals that delayed the availability of the widely promoted AndroGel testosterone replacement ...
Related articles »  
AbbVie And Abbott Get Favorable Verdict In Racketeering Lawsuit
A federal court dismissed a racketeering lawsuit yesterday against AbbVie Inc. (ABBV) and Abbott Laboratories (ABT), which accused the companies of being involved in illegal co-pay programs for the two drugs, Humira and AndroGel.
Zacks Reiterates Neutral Rating for Abbott Laboratories (ABT)
Abbott Laboratories logo Zacks restated their neutral rating on shares of Abbott Laboratories (NYSE:ABT) in a research note issued to investors on Wednesday.
Abbott Laboratories Sets New 1-Year High at $43.57 (ABT)  sleekmoney
Abbott Laboratories Earns "Neutral" Rating from Zacks (ABT)  Intercooler
Related articles »